Skip to main content
MetaVia Inc. logo

MetaVia Inc. — Investor Relations & Filings

Ticker · MTVA ISIN · US64132R1077 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US MTVA

About MetaVia Inc.

https://metaviatx.com/

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's pipeline is centered on innovative treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, DA-1726, is a dual oxyntomodulin (OXM) analog agonist that functions on both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR), under development for obesity. Another key asset is Vanoglipel, a G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for MASH.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K (Current Report) filed under Item 7.01 for Regulation FD Disclosures, attaching a press release. It is not a full Annual or Quarterly Report, nor an earnings release or capital update, nor any other specific category. As a general SEC filing for furnishing disclosure, it best fits the Regulatory Filings (RNS) fallback category.
2026-05-27 English
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K current report filed with the SEC under the Exchange Act. It provides a Regulation FD disclosure and attaches a press release as an exhibit. It does not present financial statements or detailed ESG content, nor is it a management discussion, earnings release, or other specific report type. Therefore, it falls under the general regulatory filing category.
2026-05-18 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 88% confidence The document is a U.S. SEC Form 8-K “Current Report” dated May 14, 2026, furnishing a press release on first quarter financial results (Item 2.02) and a corporate presentation under Regulation FD (Item 7.01). It does not contain the full earnings release text or actual financial statements itself, nor is it the release of a standalone report like a 10-K or interim report. It is a regulatory filing that serves primarily to furnish exhibits (the press release and investor deck). This fits the “Regulatory Filings (RNS)” category as a general SEC filing and fallback for miscellaneous announcements of filings and furnishing of materials.
2026-05-14 English
8-K - MetaVia Inc. (0001638287) (Filer)
Regulatory Filings Classification · 93% confidence The document is a Form 8-K current report under the Securities Exchange Act presenting a Regulation FD disclosure and a press release attachment. It does not contain full financial statements or interim report data, nor is it announcing dividend rates, share issues, management changes, or similar specific actions. It is a general regulatory compliance filing (Form 8-K) and therefore fits the “Regulatory Filings” category.
2026-05-11 English
ARS - MetaVia Inc. (0001638287) (Filer)
Annual Report
2026-04-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.